Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT02728544
Other study ID # shaaraZMC
Secondary ID
Status Not yet recruiting
Phase N/A
First received February 17, 2016
Last updated April 4, 2016
Start date April 2016
Est. completion date March 2017

Study information

Verified date March 2016
Source Shaare Zedek Medical Center
Contact Gross Tsur Varda, Prof.
Phone 972-2-6666239
Email gros@szmc.org.il
Is FDA regulated No
Health authority Israel: Ethics Commission
Study type Interventional

Clinical Trial Summary

Post exercise irisin levels in PWS patients Obesity, short stature, hypogonadism, hypotonia and impaired cognition are the major clinical features of Prader-Willi syndrome (PWS), a complex neurogenetic disorder due to lack of expression of paternal genes in the chromosomal region 15q11-13. Abnormal body composition with decreased muscle mass and increased fat mass contributes to low resting energy expenditure in PWS. Severe caloric restriction in the range of 800 kcal per day along with daily exercise regimens are needed to prevent weight gain and complications of obesity in this population.

Brown adipose tissue (BAT) once thought to be present only in infants, but now known to be present in adults as well, differs from the more abundant white adipose tissue (WAT) by dissipating energy through thermogenesis as a result of increased activity of the mitochondrial uncoupling protein (UCP-1). Recently evidence shows that exercise activates mitochondrial UCP-1 in subcutaneous WAT cells resulting in conversion of WAT to BAT-like adipocytes (Beige or BRITE adipose tissue). Various factors including natriuretic peptides, interleukin-6 and myokines (irisin, fibroblast growth factor 21, and ß-aminoisobutyric acid) appear to mediate the effects of exercising muscle on subcutaneous adipocytes.

Decreased amount and/or activity of BAT might contribute to the lower energy expenditure and extreme difficulty in weight-control in PWS. Lower levels or decreased myokine production could result in failure to convert subcutaneous WAT to Beige or BAT-like adipocytes, and therefore minimize or negate the otherwise beneficial metabolic effects of exercise. Direct measurement of peak oxygen uptake in PWS adults show that this population has markedly lower VO2 values compared with normal BMI-matched controls. BAT activity in vivo can be accurately measured only by performing PET/CT scans which include administrating radioactive tracers. For ethical reasons, direct assessment of BAT is not possible for purposes of clinical research in PWS individuals.

The investigators propose to study humoral responses to exercise in 16 (8 males) PWS adolescents and young adults and compare results with responses in a similar number of sex, age, and BMI-matched controls. At an initial one-hour meeting study participants will learn to perform aerobic (treadmill) exercise and resistance training under the supervision of an experienced exercise physiologist. Exercise intensity will be assessed by direct measurement of VO2 max. On a different day, a blood sample will be drawn before and immediately at the conclusion of the same exercise regimen. Blood samples will be assayed for irisin, interleukin-6, atrial natriuretic peptide, FGF-21, in addition to glucose, growth hormone, cortisol, norepinephrine, and lactate.

The investigators hypothesize that PWS participants will show weaker humoral responses to similar exercise regimens compared to normal control subjects. Data showing lower levels of myokines, such as irisin, following exercise in PWS might suggest that inadequate conversion of WAT to BAT-like adipocytes in subcutaneous adipose tissue results in decreased thermogenesis and abnormally low energy expenditure in this population. Potentially, development of pharmacologic agents which mimic irisin or other myokines by activating UCP-1 and converting WAT to BAT-like adipocytes could offer a new approach to weight-control in PWS individuals.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 32
Est. completion date March 2017
Est. primary completion date September 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

- Adult with Prader Willi syndrome

Exclusion Criteria:

- Inability to safely complete exercise regiment, heart disease or lungs disease

Study Design

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Related Conditions & MeSH terms


Intervention

Other:
exercise and blood tests
At an initial one-hour meeting study participants will learn to perform aerobic (treadmill) exercise and resistance training under the supervision of an experienced exercise physiologist. Exercise intensity will be assessed by direct measurement of VO2 m

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Shaare Zedek Medical Center

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Abnormal hormonal response 30 minutes No
See also
  Status Clinical Trial Phase
Completed NCT00742664 - Behavioral Treatment of Obsessive-Compulsive Symptoms in Youth With Prader-Willi Syndrome: A Pilot Project Phase 1/Phase 2
Completed NCT02011360 - Prader-Willi Syndrome Macronutrient Study N/A
Completed NCT02205034 - Evaluation of Tolerance, Suckling and Food Intake After Repeated Nasals Administrations of Oxytocin in PWS Infants Phase 1/Phase 2
Recruiting NCT02058342 - Family-based Intervention for Youth With Prader-Willi Syndrome: The Active Play at Home Study N/A
Completed NCT02013258 - Oxytocin Trial in Prader-Willi Syndrome Phase 1
Completed NCT02368379 - Diagnosis of Central Adrenal Insufficiency in Patients With Prader-Willi Syndrome N/A
Completed NCT01038570 - Comparative Study Between Prader-Willi Patients Who Take Oxytocin Versus Placebo Phase 2
Completed NCT01897363 - Hypoglycemia in Prader-Willi Syndrome N/A
Completed NCT01404624 - Characterization of Transcriptional Regulators of Ghrelin Hormone Which Causes Genetic Obesity N/A
Completed NCT02464514 - Macronutrient Regulation of Ghrelin and Peptide YY N/A
Terminated NCT01542242 - Liraglutide Use in Prader-Willi Syndrome Phase 4
Completed NCT00474643 - Correlation of Hyperghrelinemia With Carotid Artery Intima-Media Thickness in Children With Prader-Willi Syndrome N/A